Spark Biomedical has published a peer-reviewed study in Frontiers in Medicine showing that its wearable neurostimulation device reduced menstrual blood loss by more than 50% on average and shortened period duration by nearly 20%. The pilot study evaluated transcutaneous auricular neurostimulation for heavy menstrual bleeding.
The study included 16 participants, consisting of women with von Willebrand Disease and women with heavy menstrual bleeding of unknown cause. Participants used OhmBody‘s wearable device daily during menstruation. The device delivers neurostimulation through the ear to engage the vagus and trigeminal nerves.
“This peer-reviewed study provides the first published evidence that wearable neurostimulation can reduce heavy menstrual bleeding and improve overall menstrual wellness,” said Daniel Powell, CEO and co-founder of Spark Biomedical. “These results offer millions of women a non-invasive, drug-free option to better manage their periods.”
Participants also reported improvements in cramping, fatigue, and overall quality of life. The device works by engaging the body’s nervous system through the vagus and trigeminal nerves, providing a non-invasive approach to managing heavy menstrual bleeding.
“Heavy menstrual bleeding is a common and often under-recognized condition,” said Navid Khodaparast, Chief Science Officer and co-founder of Spark Biomedical. “Our findings suggest that wearable neurostimulation may offer a meaningful, noninvasive option to reduce menstrual blood loss and support overall menstrual health.”
OhmBody is the women’s wellness division of Spark Biomedical. The study represents the first peer-reviewed human trial evaluating transcutaneous auricular neurostimulation for menstrual health. Spark Biomedical has received funding from the NIH and Department of Defense and continues to partner with private and academic institutions.
